Tumor associated antigens and methods of using the same

Abstract

The present invention provides methods and compositions for the diagnosis of hyperproliferative disease and autoimmune disease. Tumor associated antigens, nucleic acids encoding them and antibodies to the tumor associated antigens are provided for the diagnosis of hyperproliferative disease, such as, for example, ovarian cancer, breast cancer, lung cancer, colorectal cancer, and other epithelial cancers, and for the diagnosis of autoimmune disease.

1 . A method for prognosis or diagnosis of autoimmune disease in a subject, comprising: 
 obtaining a sample from the subject, the sample comprising antibodies;    contacting the sample with at least one tumor associated antigen, the tumor associated antigen being ZFP161, Ubiquilin-1, HOX-B6, IFI27, YB-1, KIAA0136, Osteonectin, F-box only protein 21, or ILF3; and    detecting complex formation between the tumor associated antigen and the antibodies in the sample; wherein complex formation indicates a prognosis or diagnosis of autoimmune disease.    
   
   
       2 . The method of  claim 1 , wherein the subject is a mammal.  
   
   
       3 . The method of  claim 2 , wherein the subject is human.  
   
   
       4 . The method of  claim 1 , wherein the sample is blood, serum, ascites fluid, mucosal fluid, cervical wash, nipple aspirate fluid, stool, urine, saliva, tears, or sputum.  
   
   
       5 . The method of  claim 4 , wherein the sample comprises serum.  
   
   
       6 . The method of  claim 1 , wherein the detecting is by Western blot, radioimmunoassay, ELISA, sandwich immunoassay, immunoprecipitation assay, precipitin reaction, gel diffusion precipitin reaction, immunodiffusion assay, agglutination assay, complement-fixation assay, immunoradiometric assay, fluorescent immunoassay or protein A immunoassay.  
   
   
       7 . The method of  claim 1 , wherein the at least one tumor associated antigen further comprises tumor suppressor p53 or cancer-testis antigen NY-ESO-1.  
   
   
       8 . The method of  claim 1 , wherein the autoimmune disease is rheumatoid arthritis, graft versus host disease, systemic lupus erythromatosis (SLE), scleroderma, multiple sclerosis, diabetes, organ rejection, inflammatory bowel disease, or psoriasis.  
   
   
       9 . The method of  claim 1 , further comprising: 
 comparing the complex formation between the tumor associated antigen and the antibodies in the sample with complex formation of a standard to determine the prognosis or diagnosis of autoimmune disease.